Central nervous system (CNS) tumors are the eighth leading cause of cancer death and the second most common childhood cancer worldwide. Current treatment methods include surgery, radiation therapy, chemotherapy, targeted therapy, immune therapy etc. However, patients with CNS tumors usually have an unsatisfactory prognosis accompanied by impaired neurologic functions when compared with other cancers. Few drugs or treatments have been proven effective in CNS tumors due to the presence of blood-brain barriers and its distinctive tumor microenvironment.
This topic aims to bridge the gap between basic science and clinical practice, as well as to accelerate the translational process from bench to bedside. Translational research focusing on CNS tumors is welcomed:
- Novel insight into molecular information about CNS tumors (such as glioma, meningioma, medulloblastoma, brain metastasis or etc.)
- Studies devoted to developing novel treatments or identifying new targets
- Pathways to improve current therapy efficacy in an integrated manner (e.g.: neuro-genomics, neuro-pharmacy, cell biology, bioengineering, etc.) are also preferred.
We hope to provide an interactive communicating forum for central nervous system tumor therapy development and diagnosis improvement, which is including:
- New materials and techniques for artificial theranostics device updating
- New pharmacological tools to refine existing medication and explore novel lead compounds
- New genomic methods to unravel the underlying mathematics and bio-engineering mechanism within CNS tumor microenvironment.
We are also eager to accumulate interdisciplinary research exploring the associations among CNS tumors, neuroscience, and neuro-functional impairment for the broader neuroscience and neuro-oncology community.
Central nervous system (CNS) tumors are the eighth leading cause of cancer death and the second most common childhood cancer worldwide. Current treatment methods include surgery, radiation therapy, chemotherapy, targeted therapy, immune therapy etc. However, patients with CNS tumors usually have an unsatisfactory prognosis accompanied by impaired neurologic functions when compared with other cancers. Few drugs or treatments have been proven effective in CNS tumors due to the presence of blood-brain barriers and its distinctive tumor microenvironment.
This topic aims to bridge the gap between basic science and clinical practice, as well as to accelerate the translational process from bench to bedside. Translational research focusing on CNS tumors is welcomed:
- Novel insight into molecular information about CNS tumors (such as glioma, meningioma, medulloblastoma, brain metastasis or etc.)
- Studies devoted to developing novel treatments or identifying new targets
- Pathways to improve current therapy efficacy in an integrated manner (e.g.: neuro-genomics, neuro-pharmacy, cell biology, bioengineering, etc.) are also preferred.
We hope to provide an interactive communicating forum for central nervous system tumor therapy development and diagnosis improvement, which is including:
- New materials and techniques for artificial theranostics device updating
- New pharmacological tools to refine existing medication and explore novel lead compounds
- New genomic methods to unravel the underlying mathematics and bio-engineering mechanism within CNS tumor microenvironment.
We are also eager to accumulate interdisciplinary research exploring the associations among CNS tumors, neuroscience, and neuro-functional impairment for the broader neuroscience and neuro-oncology community.
